Palo Alto, United States
Surf Bio is a preclinical biopharmaceutical company with a mission to create new opportunities for biologics. Leveraging a novel biotechnology platform, Surf Bio aims to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other areas. The company was founded in 2021 by the same individuals behind Bigfoot Biomedical and Mode AGC to commercialize a breakthrough drug stabilization technology developed in the Appel Lab.
Commercially, Surf Bio's technology is designed to enable a reduction of refrigeration requirements, transition from IV to subcutaneous therapy, and novel pharmaceutical formulations across a range of therapeutic areas. In April 2022, the company received a $16.00M Seed Round investment from Breakout Ventures and Perceptive Advisors.
With a focus on the biotechnology and pharmaceutical industries, Surf Bio's innovative approach and strategic partnerships position the company for potential growth and impact in the biopharmaceutical sector.
